Nektar Therapeutics (NKTR) Stock
Key stats
- Market cap
- $1.29B
- Price / Earnings ratio
- -8.0x
- EPS (TTM)
- -$6.51
- Volume
- Loading
- 52-week high
- $109.00
- 52-week low
- $33.40
Source: third-party data provider, as of November 5, 2026
Compare with NKTR
Recent news

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
NKTR

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
NKTR

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
NKTR

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
NKTR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.88
- MACD 12/26/9
- -3.97
- EMA 9 of MACD
- -5.07
- MACD histogram
- 1.10
- SMA 50
- $53.49
- Price below SMA 50
- EMA 50
- $49.57
- Price below EMA 50
- SMA 200
- $65.03
- Price below SMA 200
- EMA 200
- $59.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$2.49 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
NKTR

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?
NKTR

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
NKTR

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
NKTR

Nektar Therapeutics Tumbles Despite Long-Term Benefit From Alopecia Drug
Nektar Therapeutics Tumbles Despite Long-Term Benefit From Alopecia Drug
NKTR

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
NKTR

Nektar Therapeutics Q2 Earnings Call Highlights
Nektar Therapeutics Q2 Earnings Call Highlights
NKTR

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
NKTR

Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?
Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?
NKTR

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
NKTR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Howard W. Robin | CEO, President & Director | 1953 |
| Ms. Linda M. Rubinstein M.A. | CFO and Principal Financial & Accounting Officer | 1967 |
| Dr. Jonathan Zalevsky Ph.D. | Senior VP and Chief Research & Development Officer | 1975 |
| Mr. Jason Barnard | Chief Accounting Officer | — |
| Ms. Elizabeth Zhang | VP of Legal, Corporate Counsel & Secretary | — |
| Mr. Robert Bacci | Chief People Officer and Head of Quality & Facilities | — |
| Ms. Jennifer Ruddock | Chief Business Officer | — |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer | 1966 |
| Dr. Ken Franke Ph.D. | Senior Vice President of Biologics Process Development & Manufacturing | — |
| Ms. Charleen Jue | Senior Vice President of Clinical Development Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 5, 2026
Technical indicators
- RSI 14
- 35.88
- MACD 12/26/9
- -3.97
- EMA 9 of MACD
- -5.07
- MACD histogram
- 1.10
- SMA 50
- $53.49
- Price below SMA 50
- EMA 50
- $49.57
- Price below EMA 50
- SMA 200
- $65.03
- Price below SMA 200
- EMA 200
- $59.23
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 4, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $50.00
- Average
- $110.17
- High
- $185.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.3 | +20.6 | ||||||||||
| 2022 | -18.6 | -7.4 | -50.9 | -26.1 | -22.7 | +7.0 | +5.6 | +4.5 | -20.4 | +19.7 | -26.5 | -21.5 |
| 2023 | +24.2 | -53.2 | -53.5 | +2.5 | -25.0 | -4.2 | -6.5 | +14.3 | -0.2 | -17.7 | +1.0 | +7.6 |
| 2024 | -8.9 | +22.4 | +19.7 | +61.5 | -23.0 | -12.1 | +9.8 | +0.8 | +4.8 | -8.5 | -7.3 | -21.2 |
| 2025 | -13.9 | +3.9 | -15.2 | +24.8 | -7.1 | +116.2 | -11.8 | +30.1 | +95.6 | +10.3 | +8.8 | -30.8 |
| 2026 | -14.0 | +81.0 | +5.3 | +12.3 | -25.0 | +9.3 | +9.8 | +1.1 | -15.6 | -17.3 | +2.2 |



